

Public Mergers & Acquisitions (US & Non-US Targets)

Deal Point Data rankings include mergers & acquisitions with a US or non-US public target and at least one SEC filer participant.

Top Target and Acquirer M&A Financial Advisers

Created: 10/Aug/2016

www.dealpointdata.com/ranking

Search Criteria

Target industry: Healthcare

Include only highest bid in pending competing deals. Exclude withdrawn deals.

Rank 2015	Rank 2014	Advice or Opinion Financial Adviser	Equity Value \$m 2015	Equity Value \$m 2014	Equity Value % Change 2014 to 2015	Deal Count 2015	Deal Count 2014
1	2	JPMorgan	68,999	102,706	-33	10	7
2	10	Morgan Stanley	66,510	9,889	573	4	3
3	1	Goldman, Sachs & Co.	53,432	142,584	-63	9	9
4	9	Citigroup Inc.	46,899	11,183	319	7	4
5	6	Centerview Partners LLC	42,693	22,747	88	5	7
6	8	Deutsche Bank AG	42,162	11,286	274	3	4
7	-	Evercore Partners	32,317	-	-	2	0
8	7	Barclays	30,919	18,051	71	1	4
8	13	Lazard	30,919	2,879	974	4	2
10	18	Guggenheim Partners	18,844	1,085	1637	4	2
11	-	HSBC	11,115	-	-	1	0
12	-	Jefferies LLC	6,750	-	-	3	0
13	14	Moelis & Company LLC	5,434	2,005	171	1	2
14	21	Leerink Partners LLC	4,915	432	1038	1	2
15	3	Bank of America Merrill Lynch	3,442	72,747	-95	1	7
16	-	Houlihan Lokey	2,018	-	-	3	0
17	15	Piper Jaffray & Co.	1,575	1,450	9	2	2
18	-	Allen & Company LLC	1,461	-	-	1	0
19	12	MTS Health Partners, L.P.	1,398	3,273	-57	1	2
19	11	Credit Suisse	1,398	4,704	-70	1	2
21	-	Rothschild Inc.	1,364	-	-	1	0
22	-	Cowen and Company, LLC	956	-	-	1	0
23	-	Ernst & Young (Israel) Ltd.	504	-	-	1	0
24	-	William Blair & Company, L.L.C.	166	-	-	1	0
25	-	Bloom Burton & Co.	128	-	-	1	0
25	-	KES VII Capital Inc.	128	-	-	1	0
27	-	Threadstone Advisors, LLC	97	-	-	1	0
28	-	Scalar Group, Inc.	71	-	-	1	0
28	-	Cassel Salpeter & Co., LLC	71	-	-	1	0

30	23	Roth Capital Partners, LLC	46	367	-87	1	1
31	20	Torrey Capital	24	625	-96	1	1
31	-	Aquilo Partners, L.P.	24	-	-	1	0
33	-	Hyde Park Capital	22	-	-	1	0

JPMorgan

Allergan plc/Pfizer Inc. \$143,317m

Auspex Pharmaceuticals, Inc./Teva Pharmaceutical Industries Ltd. \$3,213m

Bio-Reference Laboratories, Inc./OPKO Health, Inc. \$1,461m

Cellular Dynamics International, Inc./FUJIFILM Holdings Corporation \$261m

Hospira, Inc./Pfizer Inc. \$15,228m

iKang Healthcare Group, Inc./Investment Group \$1,466m

iKang Healthcare Group, Inc./Management Led Buyout \$1,044m

KYTHERA Biopharmaceuticals, Inc./Allergan plc \$1,936m

Pharmacyclics, Inc./AbbVie Inc. \$19,859m

Receptos, Inc./Celgene Corporation \$7,321m

Salix Pharmaceuticals, Ltd./Endo International plc \$11,243m

Salix Pharmaceuticals, Ltd./Valeant Pharmaceuticals International, Inc. \$11,115m

Synageva BioPharma Corp./Alexion Pharmaceuticals, Inc. \$8,394m

TriVascular Technologies, Inc./Endologix, Inc. \$211m

Morgan Stanley

Allergan plc/Pfizer Inc. \$143,317m

Baxalta Incorporated/Shire plc \$30,919m

Depomed, Inc./Horizon Pharma Public Limited Company \$1,979m

Hospira, Inc./Pfizer Inc. \$15,228m

Lumenis Ltd./XIO Group \$504m

Perrigo Company plc/Mylan N.V. \$34,105m

Pharmacyclics, Inc./AbbVie Inc. \$19,859m

Goldman, Sachs & Co.

Allergan plc/Pfizer Inc. \$143,317m

Auspex Pharmaceuticals, Inc./Teva Pharmaceutical Industries Ltd. \$3,213m

Baxalta Incorporated/Shire plc \$30,919m

Cellular Dynamics International, Inc./FUJIFILM Holdings Corporation \$261m

Foundation Medicine, Inc./Roche Holding Ltd \$1,030m

KYTHERA Biopharmaceuticals, Inc./Allergan plc \$1,936m

Lumenis Ltd./XIO Group \$504m

Mylan N.V./Teva Pharmaceutical Industries Ltd. \$40,131m

NPS Pharmaceuticals, Inc./Shire plc \$4,915m

Perrigo Company plc/Mylan N.V. \$34,105m

Synageva BioPharma Corp./Alexion Pharmaceuticals, Inc. \$8,394m

ZS Pharma, Inc./AstraZeneca PLC \$2,260m

Citigroup Inc.

Baxalta Incorporated/Shire plc \$30,919m

Depomed, Inc./Horizon Pharma Public Limited Company \$1,979m

Foundation Medicine, Inc./Roche Holding Ltd \$1,030m

Hyperion Therapeutics, Inc./Horizon Pharma Public Limited Company \$956m

IPC Healthcare, Inc./Team Health Holdings, Inc. \$1,398m

NPS Pharmaceuticals, Inc./Shire plc \$4,915m

Ocata Therapeutics, Inc./Astellas Pharma Inc. \$360m

Receptos, Inc./Celgene Corporation \$7,321m

Centerview Partners LLC

Allergan plc/Pfizer Inc. \$143,317m

Hyperion Therapeutics, Inc./Horizon Pharma Public Limited Company \$956m

Perrigo Company plc/Mylan N.V. \$34,105m

Pharmacyclics, Inc./AbbVie Inc. \$19,859m

Receptos, Inc./Celgene Corporation \$7,321m

Salix Pharmaceuticals, Ltd./Endo International plc \$11,243m

Salix Pharmaceuticals, Ltd./Valeant Pharmaceuticals International, Inc. \$11,115m

Thoratec Corporation/St. Jude Medical, Inc. \$3,442m

Deutsche Bank AG

Baxalta Incorporated/Shire plc \$30,919m

Salix Pharmaceuticals, Ltd./Valeant Pharmaceuticals International, Inc. \$11,115m

Tribute Pharmaceuticals Canada Inc./Pozen, Inc. \$128m

Evercore Partners

Baxalta Incorporated/Shire plc \$30,919m

IPC Healthcare, Inc./Team Health Holdings, Inc. \$1,398m

Barclays

Baxalta Incorporated/Shire plc \$30,919m

Mylan N.V./Teva Pharmaceutical Industries Ltd. \$40,131m

Lazard

Hospira, Inc./Pfizer Inc. \$15,228m

Mindray Medical International Limited/Management Led Buyout \$2,382m

NPS Pharmaceuticals, Inc./Shire plc \$4,915m

Synageva BioPharma Corp./Alexion Pharmaceuticals, Inc. \$8,394m

Guggenheim Partners

Allergan plc/Pfizer Inc. \$143,317m

Hospira, Inc./Pfizer Inc. \$15,228m
InSite Vision Inc./QLT Inc. \$35m
InSite Vision Inc./Sun Pharmaceutical Industries Limited \$46m
Thoratec Corporation/St. Jude Medical, Inc. \$3,442m
Tribute Pharmaceuticals Canada Inc./Pozen, Inc. \$128m

HSBC

Salix Pharmaceuticals, Ltd./Valeant Pharmaceuticals International, Inc. \$11,115m

Jefferies LLC

Depomed, Inc./Horizon Pharma Public Limited Company \$1,979m
Hyperion Therapeutics, Inc./Horizon Pharma Public Limited Company \$956m
Ocata Therapeutics, Inc./Astellas Pharma Inc. \$360m
Sirona Dental Systems, Inc./DENTSPLY International Inc. \$5,434m

Moelis & Company LLC

Allergan plc/Pfizer Inc. \$143,317m
Sirona Dental Systems, Inc./DENTSPLY International Inc. \$5,434m

Leerink Partners LLC

Depomed, Inc./Horizon Pharma Public Limited Company \$1,979m
NPS Pharmaceuticals, Inc./Shire plc \$4,915m

Bank of America Merrill Lynch

Salix Pharmaceuticals, Ltd./Endo International plc \$11,243m
Thoratec Corporation/St. Jude Medical, Inc. \$3,442m

Houlihan Lokey

Blyth, Inc./The Carlyle Group L.P. \$97m
China Cord Blood Corporation/Golden Meditech Holdings Limited \$316m
China Cord Blood Corporation/Nanjing Xinjiakou Department Store Co., Ltd. \$965m
Hyperion Therapeutics, Inc./Horizon Pharma Public Limited Company \$956m

Piper Jaffray & Co.

SORIN S.p.A./Cyberonics, Inc. \$1,364m
TriVascular Technologies, Inc./Endologix, Inc. \$211m

Allen & Company LLC

Bio-Reference Laboratories, Inc./OPKO Health, Inc. \$1,461m

MTS Health Partners, L.P.

IPC Healthcare, Inc./Team Health Holdings, Inc. \$1,398m

Credit Suisse

IPC Healthcare, Inc./Team Health Holdings, Inc. \$1,398m
Salix Pharmaceuticals, Ltd./Endo International plc \$11,243m

Rothschild Inc.

SORIN S.p.A./Cyberonics, Inc. \$1,364m

Cowen and Company, LLC

Hyperion Therapeutics, Inc./Horizon Pharma Public Limited Company \$956m

Ernst & Young (Israel) Ltd.

Lumenis Ltd./XIO Group \$504m

William Blair & Company, L.L.C.

Synergetics USA, Inc./Valeant Pharmaceuticals International, Inc. \$166m

Bloom Burton & Co.

Tribute Pharmaceuticals Canada Inc./Pozen, Inc. \$128m

KES VII Capital Inc.

Tribute Pharmaceuticals Canada Inc./Pozen, Inc. \$128m

Threadstone Advisors, LLC

Blyth, Inc./The Carlyle Group L.P. \$97m

Scalar Group, Inc.

VBI Vaccines Inc./SciVac Therapeutics Inc. \$71m

Cassel Salpeter & Co., LLC

VBI Vaccines Inc./SciVac Therapeutics Inc. \$71m

Roth Capital Partners, LLC

InSite Vision Inc./QLT Inc. \$35m
InSite Vision Inc./Sun Pharmaceutical Industries Limited \$46m

Torreya Capital

DARA BioSciences, Inc./Midatech Pharma PLC \$24m

Aquilo Partners, L.P.

DARA BioSciences, Inc./Midatech Pharma PLC \$24m

Hyde Park Capital

Unilens Vision Inc./Valeant Pharmaceuticals International, Inc. \$22m